TEV Stock Overview
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Teva Pharmaceutical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.38 |
| 52 Week High | US$9.84 |
| 52 Week Low | US$8.14 |
| Beta | 1.19 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | 11.67% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 13.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| TEV | BG Pharmaceuticals | BG Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | 0.3% |
| 1Y | 11.7% | 4.4% | 16.0% |
Return vs Industry: TEV exceeded the BG Pharmaceuticals industry which returned 1.9% over the past year.
Return vs Market: TEV matched the BG Market which returned 10.8% over the past year.
Price Volatility
| TEV volatility | |
|---|---|
| TEV Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.1% |
| Market Average Movement | 4.1% |
| 10% most volatile stocks in BG Market | 8.2% |
| 10% least volatile stocks in BG Market | 2.1% |
Stable Share Price: TEV has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine TEV's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 34,565 | Richard Francis | www.tevapharm.com |
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies.
Teva Pharmaceutical Industries Limited Fundamentals Summary
| TEV fundamental statistics | |
|---|---|
| Market cap | €10.23b |
| Earnings (TTM) | -€2.05b |
| Revenue (TTM) | €14.19b |
0.7x
P/S Ratio-5.0x
P/E RatioIs TEV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TEV income statement (TTM) | |
|---|---|
| Revenue | US$15.27b |
| Cost of Revenue | US$8.27b |
| Gross Profit | US$7.00b |
| Other Expenses | US$9.21b |
| Earnings | -US$2.21b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.97 |
| Gross Margin | 45.84% |
| Net Profit Margin | -14.46% |
| Debt/Equity Ratio | 265.9% |
How did TEV perform over the long term?
See historical performance and comparison